Latest News

Check out what is happening at HCD Economics

October 2024

Beyond the Cure: Assessing the Long-Term Gains of Curative Therapies for HIV

Over the past 30 years, antiretroviral therapy (ART) has transformed HIV into a manageable condition, drastically reducing mortality where access is available. Yet, the disease remains a significant challenge, particularly in low- and middle-income countries. Excitingly, curative therapies (CTx) might be within reach in the next 10-20 years. But addressing challenges related to pricing and financing will be essential for ensuring global access. To address these, we need to understand the economic value of CTx and develop a decision-analytic model to estimate long-term costs, health outcomes, and a value-based price for each country.
Continue Reading
August 2024

Fatigue of Joint, and Muscle Pain: The Struggles of systemic lupus erythematosus (SLE) Patients

SLE can be relentless. An inflammatory autoimmune disease that affects multiple systems within the body. It challenges patients across ethnicities, leaving them grappling with symptoms that disrupt their lives. While SLE predominantly affects black women, it also impacts Asian and Caucasian women. Unfortunately, there’s no magic cure. Instead, treatment focuses on symptom management. But what about the quality of life (QoL) of these patients? How does SLE affect their daily experiences, work, and overall well-being?
Continue Reading
July 2024

Gene Therapy: A Guided Journey for Informed Decision-Making

Gene therapy (GTx) offers a revolutionary treatment option for patients with haemophilia. It’s a one-time treatment that could potentially provide continuous protection for years. This significant treatment decision warrants a thorough understanding and careful consideration of all relevant information.
Continue Reading
Scroll for more

About us

HCD was created out of an alliance with University of Chester, charities and health service sectors in reponse to the ever-growing demand for economic analysis within healthcare and specifically the need for health economics and business intelligence within the public and third sectors.

Through these partnerships, HCD provides a unique insight and perspective, focusing our analyses on what matters to patients as well as decision-makers, all undertaken with academic rigour, independence and credibility.

Continue Reading
Scroll for more

Our Process

We have created core partnerships with University of Chester and leading patient charities that underpin our approach.

Higher education

Academia has a leading role to play in providing an independent, credible evidence-base as well as evaluating current and new ways of delivering healthcare.

Charities

Our partnerships with patient charities ensure that any analyses we undertake reflect the day-to-day realities of living with a particular condition.

Data

We apply primary or secondary real world data sources depending on research needs and questions. From ethically reviewed burden of illness studies and bespoke service primary data, to secondary sourced disease registries and episode statistics.

Scroll for more

Get in touch

...and one of our experts will get back to you ASAP.

Please be advised that we will not use your details for marketing purposes
Scroll for more
Scroll for more